Imunon CEO receives 1,593-share stock grant

Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. President and CEO Stacy Lindborg received additional equity compensation. On June 5, she was granted 1,593 shares of Imunon common stock at $2.06 per share, described as stock granted in lieu of cash for a portion of her base salary.

Following this grant, Lindborg directly holds 5,235 common shares. She also has an indirect holding of 778 common shares through a 401(k) Plan. These are compensation-related awards rather than open-market purchases or sales.

Insights

Equity compensation analyst

CEO received routine stock compensation in place of some cash salary.

Imunon granted President and CEO Stacy Lindborg 1,593 common shares at $2.06 per share, explicitly noted as stock in lieu of cash for part of her base salary. This is a non-derivative, compensation-related acquisition coded as an A transaction.

Because the shares replace cash pay, this filing reflects compensation structure rather than an active market purchase, so it carries limited signal about her view on the stock. After the grant, she directly owns 5,235 shares and holds 778 shares indirectly via a 401(k) Plan, giving a clearer picture of her current equity stake.

Insider Trade Summary

Grant/Award: 1,593 shares

Grant/Award 2 txns

Insider Lindborg Stacy

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,593	$2.06	$3K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 5,235 shares (Direct); Common Stock — 778 shares (Indirect, By 401(k) Plan)

Footnotes (1)

1. F1. Stock granted in lieu of cash for portion of base salary

Key Figures

Stock grant shares: 1,593 shares Grant price: $2.06 per share Direct holdings after grant: 5,235 shares +1 more

4 metrics

Stock grant shares 1,593 shares Common stock granted to CEO on June 5 as compensation

Grant price $2.06 per share Valuation of common stock compensation grant

Direct holdings after grant 5,235 shares CEO direct common stock ownership following Form 4 transaction

401(k) indirect holdings 778 shares Common stock held indirectly via 401(k) Plan

Key Terms

Grant, award, or other acquisition, 401(k) Plan, indirect ownership, non-derivative

4 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

401(k) Plan financial

"nature_of_ownership: By 401(k) Plan"

A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.

indirect ownership financial

"ownership_type: indirect; nature_of_ownership: By 401(k) Plan"

non-derivative financial

"transaction_type: non-derivative"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Imunon (IMNN) CEO Stacy Lindborg report in this Form 4?

Imunon President and CEO Stacy Lindborg reported receiving 1,593 shares of common stock as a grant on June 5. The shares were issued as equity compensation, replacing a portion of her base salary rather than representing an open-market stock purchase.

At what price was the Imunon (IMNN) stock grant to the CEO valued?

The stock grant to Stacy Lindborg was valued at $2.06 per share for 1,593 common shares. This reflects the price used to calculate the equity compensation amount that replaced part of her cash base salary, as disclosed in the Form 4 footnote.

How many Imunon (IMNN) shares does the CEO hold after this transaction?

After the reported grant, Stacy Lindborg directly holds 5,235 shares of Imunon common stock. She also has an indirect position of 778 shares through a 401(k) Plan, giving a combined view of her reported equity ownership in the company.

Was the Imunon (IMNN) CEO’s Form 4 transaction a market buy or sell?

The Form 4 does not show a market buy or sell. Instead, it reports a code A transaction, indicating a grant or award of 1,593 shares issued as stock in lieu of cash for a portion of Stacy Lindborg’s base salary.

What does “stock granted in lieu of cash for portion of base salary” mean for IMNN?

It means Imunon compensated CEO Stacy Lindborg by issuing 1,593 shares of common stock instead of paying that portion of her base salary in cash. This shifts some compensation into equity, aligning pay with the company’s stock performance without involving an open-market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lindborg Stacy

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		1,593(1)	A	$2.06	5,235	D
Common Stock								778	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for portion of base salary

	/s/ Susan Eylward, Attorney-in-Fact for Stacy Lindborg	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)